MDD
53
12
14
23
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
1.9%
1 terminated out of 53 trials
95.8%
+9.2% vs benchmark
15%
8 trials in Phase 3/4
43%
10 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 23 completed trials
Clinical Trials (53)
Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder
Individualized fMRI-guided TMS for Depression
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
Inhaled DMT for Major Depressive Disorder
Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
Implementation of a Self-Help Depression Program Among Orthopedic Patients
Functional Electrical Stimulation for MDD
tDCS: Sleep to Mood in Depression (S2M-D)
Take-home Functional Electrical Stimulation for MDD
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
Cancer Related Major Depression Treated With a Single Dose of Psilocybin
NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status
Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects
Dynamic Network Response to TMS Treatment
Individualized Neuromodulation for Anhedonic Depression
Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder
At-Home tDCS as Maintenance Therapy
Psilocybin rTMS for Treatment Resistant Depression
Extended Reality Behavioral Activation: An Intervention for Major Depressive Disorder
Neurofeedback to Treat Depression